Leigha Senter
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Leigha Senter has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Amanda Ewart Toland
Department of Cancer Biology and Genetics, Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, USA
13 shared publications - Shelly R. Hovick
The Ohio State University
12 shared publications - Guy N. Brock
The Ohio State University
11 shared publications - Allison DePersia
NorthShore University HealthSystem 6
10 shared publications - Amy Webb
Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus (A.W.).
10 shared publications - Ava Willoughby
The Ohio State University Wexner Medical Center 3 Columbus, Ohio
10 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Figure S1: Enhanced Risk Estimate Participant Reports.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Figure S1: Enhanced Risk Estimate Participant Reports.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Materials S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Materials S1. Baseline and Follow-up Survey Questions.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Materials S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Materials S1. Baseline and Follow-up Survey Questions.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Materials S2 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Materials S2. Survey Scoring.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Materials S2 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Materials S2. Survey Scoring.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S2 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S2. SNVs and weights used for BRCA2 88-SNV Breast PRS model.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S2 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S2. SNVs and weights used for BRCA2 88-SNV Breast PRS model.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S3 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S3. SNVs and weights used for BRCA1 Ovarian PRS model.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S3 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S3. SNVs and weights used for BRCA1 Ovarian PRS model.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S1. SNVs and weights used for BRCA1 ER- 53-SNV Breast PRS Model.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S1. SNVs and weights used for BRCA1 ER- 53-SNV Breast PRS Model.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S6 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S6. Comparison of GRE and 313-SNV breast cancer risks.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S6 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S6. Comparison of GRE and 313-SNV breast cancer risks.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S4 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S4. SNVs and weights used for BRCA2 Ovarian PRS model.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S4 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S4. SNVs and weights used for BRCA2 Ovarian PRS model.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S5 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S5. Representativeness of Study Participants.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S5 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S5. Representativeness of Study Participants.
- Open Access
- 27 June 2026
- Published by Springer Nature in Hereditary Cancer in Clinical Practice
- Vol. 24 (1)
BRCAShare: a video-based message can increase sharing of familial genetic test results
Background: Genetic testing for known familial pathogenic or likely pathogenic germline variants in cancer susceptibility genes is central to identifying relatives at heightened risk for cancer. However, current data suggest that uptake of this practice referred to as “cascade testing” remains suboptimal. Research demonstrates that healthcare providers can alleviate barriers to cascade testing by providing informational resources to facilitate patient-mediated sharing of their genetic test results with their at-risk relatives. Methods: We recruited 103 individuals with a pathogenic or likely pathogenic variant in BRCA1 or BRCA2 (BRCA1/2). Participants were randomized to receive a family communication guide with or without a 2-minute video (BRCAShare) that describes the concept of a relative’s recent diagnosis of a harmful variant in BRCA1/2 , meant to facilitate sharing of results with relatives. All participants were given surveys to assess reactions to and impact of BRCAShare across three domains: (1) participants’ sharing of genetic information and intent to share genetic information; (2) perceived susceptibility to and seriousness of BRCA1/2 cancer related risks, benefits, or barriers to intrafamilial sharing of results and cascade testing; (3) the impact of family dynamic on sharing of genetic information. Results: The group given access to the BRCAShare video (guide + video) had significantly higher odds of reporting an intent to share and actual sharing with other family members compared to those who did not receive BRCAShare (guide only). Perceptions of cancer risk did not change significantly after viewing BRCAShare, however participants demonstrated strong understanding of risks and benefits of genetic testing at baseline. There was not a significant association between family dynamics and more intent to share. Conclusions: Our research suggests that this video message is a useful method for facilitating family sharing of BRCA1 / 2 results.
- 27 June 2026
- Published by Springer Nature in Hereditary Cancer in Clinical Practice
- Vol. 24 (1)
Open AccessBRCAShare: a video-based message can increase sharing of familial genetic test results
Background: Genetic testing for known familial pathogenic or likely pathogenic germline variants in cancer susceptibility genes is central to identifying relatives at heightened risk for cancer. However, current data suggest that uptake of this practice referred to as “cascade testing” remains suboptimal. Research demonstrates that healthcare providers can alleviate barriers to cascade testing by providing informational resources to facilitate patient-mediated sharing of their genetic test results with their at-risk relatives. Methods: We recruited 103 individuals with a pathogenic or likely pathogenic variant in BRCA1 or BRCA2 (BRCA1/2). Participants were randomized to receive a family communication guide with or without a 2-minute video (BRCAShare) that describes the concept of a relative’s recent diagnosis of a harmful variant in BRCA1/2 , meant to facilitate sharing of results with relatives. All participants were given surveys to assess reactions to and impact of BRCAShare across three domains: (1) participants’ sharing of genetic information and intent to share genetic information; (2) perceived susceptibility to and seriousness of BRCA1/2 cancer related risks, benefits, or barriers to intrafamilial sharing of results and cascade testing; (3) the impact of family dynamic on sharing of genetic information. Results: The group given access to the BRCAShare video (guide + video) had significantly higher odds of reporting an intent to share and actual sharing with other family members compared to those who did not receive BRCAShare (guide only). Perceptions of cancer risk did not change significantly after viewing BRCAShare, however participants demonstrated strong understanding of risks and benefits of genetic testing at baseline. There was not a significant association between family dynamics and more intent to share. Conclusions: Our research suggests that this video message is a useful method for facilitating family sharing of BRCA1 / 2 results.